TLR3 and cholangiocarcinoma: These results provide clinical significance to further support our studies that RIPK1 represents a key mediator in TLR3 ligand, Poly(I:C)-induced cell death and -inhibited invasion, therefore CCA patients with high TLR3 and high RIPK1 expression could be benefit for this novel treatment concept.